53 Participants Needed

rAd-IFN + Celecoxib + Gemcitabine for Mesothelioma

(INFINITE Trial)

Recruiting at 42 trial locations
Pivotal Trial (Near Approval)This treatment is in the last trial phase before FDA approval
Prior Safety DataThis treatment has passed at least one previous human trial

Trial Summary

Do I need to stop my current medications to join the trial?

The trial protocol does not specify if you need to stop taking your current medications. However, there are specific time requirements for stopping certain treatments before starting the trial, such as a 21-day gap for cytotoxic chemotherapy and a 30-day gap for monoclonal antibodies. It's best to discuss your current medications with the trial team.

What data supports the effectiveness of the drug combination rAd-IFN, Celecoxib, and Gemcitabine for treating mesothelioma?

Research shows that combining COX-2 inhibitors like Celecoxib with immunotherapy can enhance the immune response against tumors, potentially leading to tumor shrinkage in mesothelioma. Additionally, studies suggest that interferons, like rAd-IFN, can boost the effectiveness of chemotherapy drugs such as Gemcitabine, making this combination a promising approach for treating mesothelioma.12345

Is the combination of rAd-IFN, Celecoxib, and Gemcitabine safe for humans?

Celecoxib and Gemcitabine have been studied for safety in humans. Celecoxib, a nonsteroidal anti-inflammatory drug, has shown potential antitumor effects in mesothelioma models, while Gemcitabine has been evaluated in clinical trials for mesothelioma, indicating some level of safety data exists for these drugs in humans.45678

What makes the rAd-IFN + Celecoxib + Gemcitabine treatment unique for mesothelioma?

This treatment is unique because it combines rAd-IFN, which boosts the immune system to fight cancer, with Celecoxib, a drug that reduces inflammation and may enhance the immune response, and Gemcitabine, a chemotherapy drug. This combination aims to improve outcomes by targeting the cancer through multiple mechanisms, including reducing the tumor's ability to suppress the immune system and directly attacking cancer cells.245910

What is the purpose of this trial?

This study will evaluate intrapleural administration of Adenovirus-Delivered Interferon Alpha-2b (rAd-IFN) in combination with Celecoxib and Gemcitabine in patients with histologically confirmed Malignant Pleural Mesothelioma (MPM) who have failed a minimum of 1 treatment regimen and a maximum of 2 treatment regimens, 1 of which must have been an anti-folate and platinum combination regimen.Eligible patients will be randomized 1:1 to either:1. Treatment group: rAd-IFN + Celecoxib followed by Gemcitabine2. Control group: Celecoxib followed by GemcitabinePatients randomized to the treatment group will receive rAd-IFN administered into the pleural space via an Intrapleural catheter (IPC) or similar intrapleural device on study Day 1.The primary objective of this study is to compare the overall survival (OS) associated with rAd IFN, when administered with celecoxib and gemcitabine, versus that associated with celecoxib and gemcitabine alone for the treatment of patients with MPM

Research Team

DS

Daniel Sterman, MD

Principal Investigator

NYU Langone Laura and Isaac Perlmutter Cancer Center

Eligibility Criteria

This trial is for adults with Malignant Pleural Mesothelioma who've had 1-2 prior treatments, including an anti-folate and platinum regimen. They must be able to undergo intrapleural therapy, have a life expectancy of at least 12 weeks, and be in good physical condition (ECOG status 0 or 1). Women must not be pregnant and agree to contraception; men also need to use contraception.

Inclusion Criteria

The doctor thinks you have about 12 weeks to live.
I am fully active or restricted in physically strenuous activity but can do light work.
I am a woman who cannot have children because I am postmenopausal or have been surgically sterilized.
See 9 more

Exclusion Criteria

You have had problems digesting galactose or glucose in the past.
My cancer has spread beyond my chest to other parts of my body.
My blood pressure is very high and not well-managed.
See 21 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

4 weeks

Treatment

Participants receive rAd-IFN, celecoxib, and gemcitabine or celecoxib and gemcitabine alone

Until disease progression or early termination
Regular visits every 3 weeks for gemcitabine administration

Follow-up

Participants are monitored for survival and safety every 6 months for up to 5 years

60 months
Every 6 months

Treatment Details

Interventions

  • Celecoxib Oral Product
  • Gemcitabine
  • rAd-IFN
Trial Overview The study tests rAd-IFN given through the chest cavity along with Celecoxib and Gemcitabine versus just Celecoxib and Gemcitabine. The goal is to see if adding rAd-IFN improves survival. Patients are randomly assigned to either the treatment group receiving all three drugs or the control group receiving only two.
Participant Groups
2Treatment groups
Active Control
Placebo Group
Group I: Treatment GroupActive Control3 Interventions
rAd-IFN (Study Day 1) + celecoxib (Study Days 1 to 14) + gemcitabine (Study Days 14 and 21 \[i.e., Days 1 and 8 of the first gemcitabine treatment cycle\], gemcitabine will be administered on a 21-day cycle, unless the cycle is modified due to toxicity/delay, and repeated every 3 weeks until disease progression/early termination \[ET\]
Group II: Control GroupPlacebo Group2 Interventions
Celecoxib (Study Days 1 to 14) + gemcitabine (Study Days 14 and 21 \[i.e., Days 1 and 8 of the first gemcitabine treatment cycle\], gemcitabine will be administered on a 21-day cycle, unless the cycle is modified due to toxicity/delay, and repeated every 3 weeks until disease progression/ET.

Find a Clinic Near You

Who Is Running the Clinical Trial?

Ferring Ventures Limited

Lead Sponsor

Trials
1
Recruited
50+

Trizell Ltd

Lead Sponsor

Trials
1
Recruited
50+

University of Pennsylvania

Collaborator

Trials
2,118
Recruited
45,270,000+

Findings from Research

In a phase II study involving 50 patients with unresectable malignant mesothelioma, the combination of gemcitabine and cisplatin showed a modest overall response rate of 12%, with one complete response and five partial responses, primarily in patients with specific tumor histologies.
The treatment resulted in a median overall survival of 10 months and a median progression-free survival of 6 months, with an acceptable safety profile, although 16 patients experienced Grade 4 toxicities, mainly hematologic, and there were no treatment-related deaths.
Gemcitabine and cisplatin in unresectable malignant mesothelioma of the pleura: a phase II study of the Southwest Oncology Group (SWOG 9810).Kalmadi, SR., Rankin, C., Kraut, MJ., et al.[2022]

References

Combined regimen of cisplatin, doxorubicin, and alpha-2b interferon in the treatment of advanced malignant pleural mesothelioma: a Phase II multicenter trial of the Italian Group on Rare Tumors (GITR) and the Italian Lung Cancer Task Force (FONICAP). [2022]
[A case report of disseminated malignant mesothelioma of peritoneum responding remarkably to thalidomide, celecoxib, vinorelbine and CDDP]. [2018]
A trial of intrapleural adenoviral-mediated Interferon-α2b gene transfer for malignant pleural mesothelioma. [2021]
Use of cyclooxygenase-2 inhibition to enhance the efficacy of immunotherapy. [2014]
Piroxicam and cisplatin in a mouse model of peritoneal mesothelioma. [2013]
Efficacy of piroxicam plus cisplatin-loaded PLGA nanoparticles in inducing apoptosis in mesothelioma cells. [2022]
Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial. [2023]
Preclinical evaluation of the nonsteroidal anti-inflammatory agent celecoxib on malignant mesothelioma chemoprevention. [2021]
The role of gemcitabine in the treatment of malignant mesothelioma. [2022]
Gemcitabine and cisplatin in unresectable malignant mesothelioma of the pleura: a phase II study of the Southwest Oncology Group (SWOG 9810). [2022]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security